Mehran Sugar Mills Limited (PSX:MRNS)
59.78
+1.78 (3.07%)
At close: Mar 5, 2026
Mehran Sugar Mills Revenue
Mehran Sugar Mills had revenue of 1.35B PKR in the quarter ending December 31, 2025, a decrease of -65.44%. This brings the company's revenue in the last twelve months to 11.02B, down -16.50% year-over-year. In the fiscal year ending September 30, 2025, Mehran Sugar Mills had annual revenue of 13.57B with 23.52% growth.
Revenue (ttm)
11.02B
Revenue Growth
-16.50%
P/S Ratio
0.41
Revenue / Employee
40.06M
Employees
275
Market Cap
4.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 13.57B | 2.58B | 23.52% |
| Sep 30, 2024 | 10.99B | 5.34M | 0.05% |
| Sep 30, 2023 | 10.98B | 4.09B | 59.23% |
| Sep 30, 2022 | 6.90B | 834.49M | 13.76% |
| Sep 30, 2021 | 6.06B | -361.14M | -5.62% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The Thal Industries Corporation | 42.27B |
| Matco Foods | 25.54B |
| Shahmurad Sugar Mills | 21.94B |
| Habib Sugar Mills | 20.04B |
| Al-Noor Sugar Mills | 16.82B |
| The Organic Meat Company | 13.21B |
| Shezan International | 9.36B |
| Bunny's | 7.59B |
Mehran Sugar Mills News
- 1 year ago - MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS - Business Wire
- 1 year ago - Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. - Business Wire
- 1 year ago - Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 1 year ago - Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire
- 1 year ago - Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - Business Wire
- 1 year ago - 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity - Benzinga
- 1 year ago - Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - Business Wire
- 1 year ago - Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting - Business Wire